News

CAMBRIDGE, UK (2012-07-31) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Berwyn Clarke as a Non-Executive Director.  Dr Clarke joins the ProteinLogic Board with 25 years’ experience in diagnostics and pharmaceuticals working for start-ups and global businesses such as GlaxoWellcome and Bayer Diagnostics. He is Founder and Chief Scientific Officer of Lab21 Ltd, a rapidly growing healthcare diagnostics business, providing state-of-the-art diagnostic infectious disease products to blood-banks and clinical labs on a worldwide basis; molecular diagnostic products; and molecular diagnostic services in personalised medicine, mainly in oncology. Dr Clarke played a leading role in taking Lab21 from…

CAMBRIDGE, UK (2011-10-04) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Paul Rodgers as Executive Chairman. Dr Rodgers is an entrepreneur with thirty years’ experience in the life sciences industry, who has co-founded ten biotechnology companies. Paul has led a number of companies from start up to technology commercialisation and achieved significant exits for early stage investors. A seasoned Board Director, Paul has experience in the healthcare, agriculture and food sectors of biotechnology with particular experience in biomarkers. Most recently, Paul has served as Chairman of Psynova Neurotech Ltd, a company focused on the commercial development and…

CAMBRIDGE, UK (2010-04-27) – ProteinLogic Ltd. (“the Company”), today announced that preliminary ImmiPrint diagnostic signatures have been successfully identified for several new diseases. These encouraging results follow the completion of a range of exploratory tests of different diseases using its proprietary ImmiPrint technology. ProteinLogic has consequently now demonstrated the utility of its diagnostic technology across several different diseases and disease areas. The sensitivities and specificities make it appropriate for the Company to consider validation of some of the ImmiPrint tests. The Company believes that the new results constitute a generalised proof of concept for the ImmiPrint diagnostic biomarker discovery platform…

CAMBRIDGE, UK (2009-03-24) -FOR IMMEDIATE RELEASE ProteinLogic closes Private Placing CAMBRIDGE, UK (17th March 2009) ProteinLogic Ltd (the Company) is pleased to announce that it has raised a total of just over £426,000 from a mix of existing shareholders and a number of new investors. After taking into account the costs of the placing, ProteinLogic has a net cash balance of circa £400,000 with which to fund the continued development of the business and ProteinLogic’s ImmiPrint diagnostic technology. The directors anticipate that this funding will be sufficient to take the company through to the next major milestones in the development of…

CAMBRIDGE, UK (2008-09-30) – FOR IMMEDIATE RELEASE ProteinLogic announces collaboration with the Immune Tolerance Network CAMBRIDGE, UK (30th September, 2008) ProteinLogic Ltd. (“the Company”), announced today a collaboration with US research consortium the Immune Tolerance Network to look for disease-specific diagnostic protein fingerprints in the blood of patients with a broad range of different autoimmune diseases. This initiative is expected to lead to a more extensive relationship between ProteinLogic and the Immune Tolerance Network that will provide the Company with access to patient samples from a wide range of US autoimmune clinical trials and if successful may result in significant…